Company profile: GenEdit
1.1 - Company Overview
Company description
- Provider of a proprietary non-viral, non-lipid polymer nanoparticle platform (NanoGalaxy) for safe, efficient delivery of genetic medicine payloads—including nucleic acids, therapeutic proteins, and CRISPR/Cas9—to specific tissues. Offers tissue selectivity, payload flexibility, ability to redose without immune response, and scalable manufacturing with batch-to-batch purity and long-term stability that reduces cold-chain logistics.
Products and services
- NanoGalaxy® Platform: Polymer-based library of non-viral nanoparticles delivering genetic medicine payloads to specific tissues, enabling redosing without immune response and scalable manufacture with batch purity, long-term stability, and reduced cold-chain logistics
- Payload Flexibility: Modular capability using polymer nanoparticles to encapsulate and deliver nucleic acids, therapeutic proteins, and CRISPRs, supporting multiple genetic medicine payload types
- Tissue Selectivity: Precision-targeted feature directing nanoparticles to specific tissues to enhance therapeutic efficacy and safety by localizing genetic medicine delivery.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to GenEdit
Krystal Biotech
HQ: United States
Website
- Description: Provider of gene therapies, including FDA-approved VYJUVEK for delivering missing or defective genes to the skin; with focus on Autosomal Recessive Congenital Ichthyosis, Netherton Syndrome, Cystic Fibrosis, and Alpha-1 Antitrypsin Deficiency; and oncology development using a modified HSV-1 vector to deliver IL-12 and IL-2 to the tumor microenvironment for immune-mediated tumor clearance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Krystal Biotech company profile →
Crescendo Bioscience
HQ: United States
Website
- Description: Provider of quantitative, objective diagnostic tools for rheumatologists, delivering clinical insights to manage patients with autoimmune and inflammatory diseases. Provides diagnostic, prognostic, staging, therapy selection, and monitoring facilities to physicians.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Crescendo Bioscience company profile →
Adverum Biotechnologies
HQ: United States
Website
- Description: Provider of gene therapy, developing medicines with therapeutic benefits. Offerings include Ixo-vec, a gene therapy product candidate for wet age-related macular degeneration designed for single administration, and the OPTIC clinical program investigating the safety, efficacy, and long-term outcomes of Ixo-vec in wet AMD patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Adverum Biotechnologies company profile →
Lysogene
HQ: France
Website
- Description: Provider of basic research and clinical development of gene therapy for neurodegenerative disorders, developing AAV vectors, with a mission to improve the health of patients with incurable, life-threatening conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lysogene company profile →
Rancho BioSciences
HQ: United States
Website
- Description: Provider of fee-for-service life science data curation and knowledge management, leveraging open-source tools and public domain data for Pharma, non-profit foundations, and academia. Services include data curation, data governance and models, bioinformatics analysis (including genetic variant annotation), workflows and pipelines, knowledge mining, and creation of target profiles to support research and development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rancho BioSciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for GenEdit
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to GenEdit
2.2 - Growth funds investing in similar companies to GenEdit
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for GenEdit
4.2 - Public trading comparable groups for GenEdit
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →